Collegium Pharmaceutical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Vikram Karnani
- Full Time Employees
- 423
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 100 Technology Center Drive Stoughton MA United States of America 02072
- IPO Date
- May 7, 2015
- CIK
- 0001267565
- Website
- collegiumpharma.com
- Similar Companies
- Business
- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is a diversified biopharmaceutical company focused on developing, licensing, and commercializing differentiated medications for serious medical conditions, including moderate to severe pain and attention deficit hyperactivity disorder (ADHD); its commercial portfolio features Jornay PM, a central nervous system stimulant for ADHD treatment taken in the evening; Belbuca, a buprenorphine-containing buccal film for persistent pain requiring around-the-clock opioid analgesia; Xtampza ER, an abuse-deterrent extended-release oral oxycodone formulation; Nucynta ER and Nucynta IR, extended-release and immediate-release tapentadol products for severe pain management; and Symproic, an opioid antagonist available in the United States. Founded in 2002 and headquartered in Stoughton, Massachusetts, the company operates primarily in the U.S. market, leveraging its DETERx platform technology for abuse-deterrent formulations and pursuing growth in pain management and neuropsychiatry segments through strategic portfolio expansion. In late 2024, Collegium completed the US$525 million acquisition of Ironshore Pharmaceuticals, integrating Jornay PM to establish a foothold in ADHD treatment and diversify beyond opioids; it also launched a US$150 million share repurchase program in early 2024, executing a US$25 million accelerated share repurchase in May 2025 while reporting 23% year-over-year revenue growth in the first quarter of 2025 driven by pain products and Jornay PM.
Company News
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut
Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
New Strong Sell Stocks for October 7th
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Collegium to Participate in Upcoming Investor Conferences
44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP
BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL
A Look at Collegium Pharmaceutical Inc (COLL) After 3.9% Decline -- GF Value $47.17 vs Price $26.39
Collegium Announces $50 Million Accelerated Share Repurchase Program
Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical Q2 Earnings Call Highlights
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
Bessemer Group Inc. Acquires 31,800 Shares of Collegium Pharmaceutical, Inc. $COLL
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln